Tumor necrosis factor α promoter polymorphisms at position -308 in Taiwanese chronic hepatitis C patients treated with interferon-alpha

Antiviral Research

Volumn 59, Issue 1, 2003, Pages 35-40

  Yu, Ming Lung ^a   Dai, Chia Yen ^a   Chiu, Chao Chin ^a   Lee, Li Po ^a   Lin, Zu Yau ^a   Chen, Shinn Cherng ^a   Hsieh, Ming Yuh ^a   Wang, Liang Yen ^a   Chen, Chung Jen ^a   Chuang, Wan Long ^a   Chang, Wen Yu ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

HCV; IFN; TNF promoter gene polymorphism

Indexed keywords

AMINOTRANSFERASE; RECOMBINANT ALPHA2B INTERFERON; TUMOR NECROSIS FACTOR ALPHA; VIRUS RNA;

ADULT; AGE; AGED; ARTICLE; ASIAN; BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG RESPONSE; FEMALE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; INFECTION SENSITIVITY; INFLAMMATION; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATHOGENESIS; PATIENT; PRIORITY JOURNAL; PROMOTER REGION; SEX DIFFERENCE; VIRUS GENE;

HEPATITIS C VIRUS;

EID: 0038460862     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(03)00029-9     Document Type: Article

References (36)

1. Allen R.D. Polymorphism of the human TNF-alpha promoter: random variation or functional diversity? Mol. Immunol. 36:1999;1017-1027.
2. Alter M.J., Margolis H.S., Krawczynski K., Judson F.N., Mares A., Alexander W.J.et al. The natural history of community-acquired hepatitis C in the United States. New Engl. J. Med. 327:1992;1899-1905.
3. Bradham C.A., Plumpe J., Manns M.P., Brenner D.A., Trautwein C. Mechanisms of hepatic toxicity. I. TNF-induced liver injury. Am. J. Physiol. 275:1998;387-392.
4. Brinkman B.M., Zuijdeest D., Kaijzel E.L., Breedveld F.C., Verweij C.L. Relevance of the tumor necrosis factor alpha (TNF-alpha) -308 promoter polymorphism in TNF-alpha gene regulation. J. Inflamm. 46:1996;32-41.
5. Cabrera M., Shaw M.A., Sharples C., Williams H., Castes M., Convit J., Blackwell J.M. Polymorphism in tumor necrosis factor genes associated with mucocutaneous leishmaniasis. J. Exp. Med. 182:1995;1259-1264.
6. Castes M., Trujillo D., Rojas M.E., Fernandez C.T., Araya L., Cabrera M., Blackwell J., Convit J. Serum levels of tumor necrosis factor in patients with American cutaneous leishmaniasis. Biol. Res. 26:1993;233-238.
7. D'Alfonso S., Richiardi P.M. A polymorphic variation in a putative regulation box of the TNF: a promoter region. Immunogenetics. 39:1994;150-155.
8. Dunstan S.J., Stephens H.A., Blackwell J.M., Duc C.M., Lanh M.N., Dudbridge F., Phuong C.X., Luxemburger C., Wain J., Ho V.A., Hien T.T., Farrar J., Dougan G. Genes of the class II and class III major histocompatibility complex are associated with typhoid fever in Vietnam. J. Infect. Dis. 183:2001;261-268.
9. Galbraith G.M., Steed R.B., Sanders J.J., Pandey J.P. Tumor necrosis factor alpha production by oral leukocytes: influence of tumor necrosis factor genotype. J. Periodontol. 69:1998;428-433.
10. Gonzalez-Peralta R.P., Davis G.L., Lau J.Y. Pathogenetic mechanisms of hepatocellular damage in chronic hepatitis C virus infection. J. Hepatol. 21:1994;255-259.
11. Hohler T., Kruger A., Gerken G., Schneider P.M., Meyer zum Buschenfelde K.H., Rittner C. Tumor necrosis factor alpha promoter polymorphism at position -238 is associated with chronic active hepatitis C infection. J. Med. Virol. 54:1998;173-177.
12. Kinnman N., Andersson U., Hultcrantz R. In situ expression of transforming growth factor-beta1-3, latent transforming growth factor-beta binding protein and tumor necrosis factor-alpha in liver tissue from patients with chronic hepatitis C. Scand. J. Gastroenterol. 3512:2000;1294-1300.
13. Knodell R.G., Ishak K.G., Black W.C., Chen T.S., Craig R., Kaplowitz N., Kiernan T.W., Wollman J. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1:1981;431-435.
14. Koziel M.J. Cytokines in viral hepatitis. Sem. Liver Dis. 19:1999;157-169.
15. Kwiatkowski D., Hill A.V.S., Sambou I., Twumasi P., Castracane J., Manogue K.R., Cerami A., Brewster D.R., Greenwood B.M. TNF concentration in fatal cerebral malaria, non-fatal cerebral, and uncomplicated Plasmodium falciparum malaria, non-fatal cerebral, and uncomplicated Plasmodium falciparum malaria. Lancet. 336:1990;1201-1204.
16. Larrea E., Garcia N., Qian C., Civeira M.P., Prieto J. Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C. Hepatology. 23:1996;210-217.
17. Lauer G.M., Walker B.D. Hepatitis C virus infection. New Engl. J. Med. 345:2001;41-52.
18. McGuire W., Hill A.V.S., Allsopp C.E.M., Greenwood B.M., Kwiatkowski D. Variation in the TNF-α promoter region associated with susceptibility to cerebral malaria. Nature. 371:1994;508-511.
19. Nokta M., Matzke D., Jennings M., Schlick E., Nadler P.I., Pollard R. In vivo administration of tumor necrosis factor-alpha is associated with antiviral activity in human peripheral mononuclear cells. Proc. Soc. Exp. Biol. Med. 197:1991;144-149.
20. Okamoto H., Tokita H., Sakamoto M., Horikita M., Kojima M., Iizuka H., Mishiro S. Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection. J. Genet. Virol. 74:1993;2385-2390.
21. Peters M. Actions of cytokines on the immune response and viral interactions: an overview. Hepatology. 23:1996;909-916.
22. Rood M.J., van Krugten M.V., Zanelli E., van der Linden M.W., Keijsers V., Schreuder G.M., Verduyn W., Westendorp R.G., de Vries R.R., Breedveld F.C., Verweij C.L., Huizinga T.W. TNF308A and HLA-DR3 alleles contribute independently to susceptibility to systemic lupus erythematosus. Arthritis Rheum. 43:2000;129-134.
23. Rosen H.R., Lentz J.J., Rose S.L., Rabkin J., Corless C.L., Taylor K., Chou S. Donor polymorphism of tumor necrosis factor gene: relationship with variable severity of hepatitis C recurrence after liver transplantation. Transplantation. 68:1999;1898-1902.
24. Rubin B.Y. TNF and viruses: multiple interrelationships. Immunol. Ser. 56:1992;331-340.
25. Takaki A., Wiese M., Maertens G., Depla E., Seifert U., Liebetrau A., Miller J.L., Manns M.P., Rehermann B. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat. Med. 6:2000;578-582.
26. Tanaka A., Quaranta S., Mattalia A., Coppel R., Rosina F., Manns M., Gershwin M.E. The tumor necrosis factor-alpha promoter correlates with progression of primary biliary cirrhosis. J. Hepatol. 30:1999;826-829.
27. Tilg H., Wilmer A., Vogel W., Herold M., Nölchen B., Judmaier G., Huber C. Serum levels of cytokines in chronic liver diseases. Gastroenterology. 103:1992;264-273.
28. Torre D., Zeroli C., Giola M., Ferrario G., Fiori G.P., Bonetta G., Tambini R. Serum levels of interleukin-1a, interleukin-1b, interleukin-6, and tumour necrosis factor in patients with acute viral hepatitis. Clin. Infect. Dis. 18:1994;194-198.
29. *2 marks high risk of severe disease during Plasmodium falciparum malaria and other infections in Sri Lankans. Clin. Exp. Immunol. 115:1999;350-355.
30. Wilson A.G., di Giovine F.S., Blakemore A.I., Duff G.W. Single base polymorphism in the human tumour necrosis factor alpha (TNF-alpha) gene detectable by NcoI restriction of PCR product. Hum. Mol. Genet. 1:1992;353.
31. Wilson A.G., Symons J.A., McDowell T.L., McDevitt H.O., Duff G.W. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc. Natl. Acad. Sci. U.S.A. 94:1997;3195-3199.
32. Wong G.H., Krowka J.F., Stites D.P., Goeddel D.V. In vitro anti-human immunodeficiency virus activities of tumor necrosis factor-alpha and interferon-gamma. J. Immunol. 1:1988;120-124.
33. Yee L.J., Tang J., Herrera J., Kaslow R.A., Van Leeuwen D.J. Tumor necrosis factor gene polymorphisms in patients with cirrhosis from chronic hepatitis C virus infection. Genes Immun. 1:2000;386-390.
34. Yee L.J., Tang J., Gibson A.W., Kimberly R., Van Leeuwen D.J., Kaslow R.A. Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology. 33:2001;708-712.
35. Yu M.-L., Chuang W.-L., Dai C.-Y., Chen S.-C., Lin Z.-Y., Hsieh M.-Y., Wang L.-Y., Chang W.-Y. Clinical evaluation of the automated COBAS AMPLICOR HCV MONITOR test version 2.0 for quantifying serum hepatitis C virus RNA and comparison to the Quantiplex HCV version 2.0 test. J. Clin. Microbiol. 38:2000;2933-2939.
36. Yu M.-L., Chuang W.-L., Chen S.-C., Dai C.-Y., Hou C., Wang J.H., Lu S.N., Huang J.F., Lin Z.-Y., Hsieh M.-Y., Tsai J.F., Wang L.-Y., Chang W.-Y. Changing prevalence of hepatitis C virus genotypes: molecular epidemiology and clinical implications in the hepatitis C virus hyperendemic areas and a Tertiary Referral Center in Taiwan. J. Med. Virol. 65:2001;58-65.